Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mike Boggild

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
JAMA Neurology|July 2, 2016
Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United KingdomPedro María Rodríguez Cruz, Lucy Matthews, Mike Boggild, et al.
Brain : a Journal of Neurology|May 12, 2012
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and JapanJoanna Kitley, M Isabel Leite, Ichiro Nakashima, et al.
European Journal of Neurology|March 9, 2022
Diagnosis, differential diagnosis and misdiagnosis of Susac syndromeJames D Triplett, Jessica Qiu, Billy O'Brien, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Neurology|November 5, 2015
Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromesMaciej Juryńczyk, Brian Weinshenker, Gulsen Akman-Demir, et al.
The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Multiple Sclerosis and Related Disorders|February 26, 2022
Response to treatment in NMOSD: the Australasian experienceLaura Clarke, Wajih Bukhari, Cullen M O'Gorman, et al.
Clinical Neurology and Neurosurgery|May 29, 2012
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosisYara Dadalti Fragoso, Mike Boggild, Miguel Angel Macias-Islas, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
JAMA Neurology|July 2, 2016
Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United KingdomPedro María Rodríguez Cruz, Lucy Matthews, Mike Boggild, et al.
Brain : a Journal of Neurology|May 12, 2012
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and JapanJoanna Kitley, M Isabel Leite, Ichiro Nakashima, et al.
European Journal of Neurology|March 9, 2022
Diagnosis, differential diagnosis and misdiagnosis of Susac syndromeJames D Triplett, Jessica Qiu, Billy O'Brien, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Neurology|November 5, 2015
Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromesMaciej Juryńczyk, Brian Weinshenker, Gulsen Akman-Demir, et al.
The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Multiple Sclerosis and Related Disorders|February 26, 2022
Response to treatment in NMOSD: the Australasian experienceLaura Clarke, Wajih Bukhari, Cullen M O'Gorman, et al.
Clinical Neurology and Neurosurgery|May 29, 2012
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosisYara Dadalti Fragoso, Mike Boggild, Miguel Angel Macias-Islas, et al.
Pageof 6